Articles Referencing AGN
Patent Challenge from Perrigo - Analyst Blog
5/31/2013, 6:28 pm from Zacks.com in Investing, Business, Stocks
Perrigo Company ( PRGO ) recently
announced that it is seeking US approval to market its generic
version of Eli Lilly and Company 's ( LLY ) Axiron. The drug
is marketed for treating... Read >>
Allergan, Inc. (AGN) Ex-Dividend Date Scheduled for May 21, 2013
5/20/2013, 9:00 am from NASDAQ.com News in News Headlines, Stocks
Allergan, Inc. ( AGN ) will begin
trading ex-dividend on May 21, 2013. A cash dividend payment of
$0.05 per share is scheduled to be paid on June 13, 2013.
Shareholders who purchased AGN stock... Read >>
New Stock Coverage: Frozen Smiles All Around at Allergan
5/10/2013, 9:18 am from Minyanville in Investing, Stocks
When Michael J. Fox, that perpetually youthful money-making teen
from Family Ties , finds himself on the front cover of AARP Magazine , maybe
it's a sign that the record run in equities has... Read >>
Positive Opinion on Allergan Candidate - Analyst Blog
5/6/2013, 5:23 pm from Zacks.com in Investing, Business, Stocks
Allergan, Inc. ( AGN ) recently received
encouraging news when the US Food and Drug Administration's (FDA)
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory... Read >>
New Stock Coverage: Put Fresh Money to Work in Fossil
5/3/2013, 9:17 am from Minyanville in Investing, Stocks
"Sell in May and go away" doesn't work so well when it's Christmas in April . Positive employment data
from Challenger, Gray & Christmas, allied with a slew of solid
earnings... Read >>
Allergan Beats on Earnings - Analyst Blog
5/1/2013, 1:03 pm from Zacks.com in Investing, Business, Earnings, Stocks
Allergan, Inc. ( AGN ) reported first
quarter 2013 earnings of 98 cents per share, beating the Zacks
Consensus Estimate of 96 cents per share by 2 cents.
While earnings increased 18.1%... Read >>
Pre-Market Earnings Report for May 1, 2013 : MRK, CMCSA, CVS, MA, TWX, AGN, AMT, EXC, VIAB, DVN, DLPH, CHK
4/30/2013, 4:00 pm from NASDAQ.com News in News Headlines, Earnings
The following companies are expected to report earnings prior to
market open on 05/01/2013. Visit our Earnings
Calendar for a full list of expected earnings releases. Merck & Company,... Read >>
A Look at LLY's Early Stage Oncology Pipeline - Analyst Blog
4/12/2013, 3:50 pm from Zacks.com in Investing, Business, Stocks
Eli Lilly and Company ( LLY ) recently provided
an update on its early-stage oncology pipeline at the annual
meeting of the American Association for Cancer Research (AACR). The company... Read >>
Roche Reports 1Q Sales - Analyst Blog
4/12/2013, 2:06 pm from Zacks.com in Investing, Business, Stocks
Roche Holdings Ltd. ( RHHBY ) recently
reported results for the first quarter of 2013. Revenues grew
6% year over year to CHF 11.6 billion driven by solid demand for
its cancer drugs... Read >>
SNY's Vaxigrip Filing Accepted in EU - Analyst Blog
4/11/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
Sanofi ( SNY ) recently
announced that a decentralized marketing authorization application
(MAA) for its quadrivalent flu vaccine, Vaxigrip, has been accepted
for review in the EU.
The... Read >>
Roche's New Test for Thyroid Cancer - Analyst Blog
4/11/2013, 5:09 pm from Zacks.com in Investing, Business, Stocks
Roche ( RHHBY ) recently
launched a new laboratory test, Elecsys Calcitonin, to diagnose and
monitor thyroid cancer. The test uses Roche's cobas modular
analyser platform and enables... Read >>
SNY's Aubagio Gets Argentinean Nod - Analyst Blog
4/10/2013, 5:11 pm from Zacks.com in Investing, Business, Stocks
Sanofi 's ( SNY ) subsidiary
Genzyme recently announced that its oral candidate for relapsing
forms of multiple sclerosis (RMS), Aubagio (teriflunomide) 14 mg,
has gained approval from... Read >>
Priority Review for Bayer's Riociguat - Analyst Blog
4/9/2013, 4:08 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received encouraging news from the US Food and
Drug Administration (FDA) as it granted priority review designation
to the New Drug Application... Read >>
Valeant: The Sole Suitor for Obagi - Analyst Blog
4/9/2013, 3:09 pm from Zacks.com in Investing, Business, Stocks
Valeant Pharmaceuticals ' ( VRX ) proposed
acquisition of Obagi Medical Products, Inc. ( OMPI ) received a
boost with Merz Pharma Group opting out of the race to purchase
Obagi. Merz's... Read >>
Valeant Ups Offer for Obagi - Analyst Blog
4/4/2013, 6:07 pm from Zacks.com in Investing, Business, Stocks
Valeant Pharmaceuticals ( VRX ) recently
announced that the company has increased its offer price to acquire
Obagi Medical Products, Inc. ( OMPI ). As per the new agreement, Valeant... Read >>